Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: OnabotulinumtoxinA is used widely for the treatment of neurogenic detrusor overactivity. We conducted a systematic review and meta-analysis to assess its efficacy and safety for neurogenic detrusor overactivity treatment. Methods: A systematic literature review was performed to identify all published randomized double-blind, placebo-controlled trials of onabotulinumtoxinA for neurogenic detrusor overactivity treatment. MEDLINE, Embase, and the CENTRAL were employed. Reference lists of retrieved studies were reviewed carefully. Results: Six publications involving 871 patients, which compared onabotulinumtoxinA with a placebo were analyzed. Efficacy of onabotulinumtoxinA treatment was shown as a reduction of the mean number of urinary incontinence episodes per day (mean difference, -1.41; 95% confidence interval [CI], -1.70 to -1.12; P<0.00001), maximum cystometric capacity (135.48; 95% CI, 118.22–152.75; P<0.00001), and maximum detrusor pressure (-32.98; 95% CI, -37.33 to -28.62; P<0.00001). Assessment of adverse events revealed that complications due to onabotulinumtoxinA injection were localized primarily to the urinary tract. Conclusions: This meta-analysis suggests that onabotulinumtoxinA is an effective treatment for neurogenic detrusor overactivity with localized advent events
Abstract
Purpose: OnabotulinumtoxinA is used widely for the treatment of neurogenic detrusor overactivity. We conducted a systematic review and meta-analysis to assess its efficacy and safety for neurogenic detrusor overactivity treatment. Methods: A systematic literature review was performed to identify all published randomized double-blind, placebo-controlled trials of onabotulinumtoxinA for neurogenic detrusor overactivity treatment. MEDLINE, Embase, and the CENTRAL were employed. Reference lists of retrieved studies were reviewed carefully. Results: Six publications involving 871 patients, which compared onabotulinumtoxinA with a placebo were analyzed. Efficacy of onabotulinumtoxinA treatment was shown as a reduction of the mean number of urinary incontinence episodes per day (mean difference, -1.41; 95% confidence interval [CI], -1.70 to -1.12; P<0.00001), maximum cystometric capacity (135.48; 95% CI, 118.22–152.75; P<0.00001), and maximum detrusor pressure (-32.98; 95% CI, -37.33 to -28.62; P<0.00001). Assessment of adverse events revealed that complications due to onabotulinumtoxinA injection were localized primarily to the urinary tract. Conclusions: This meta-analysis suggests that onabotulinumtoxinA is an effective treatment for neurogenic detrusor overactivity with localized advent events
참고문헌 (32)
- Abrams P, "The standardisation of terminology in lower urinary tract function : report from the standardisation sub-committee of the International Continence Society", Urology, 61, pp.37~49 (2003)
- Abrams P, "The standardisation of terminology of lower urinary tract function : report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Stöhrer M, "EAU guidelines on neurogenic lower urinary tract dysfunction", Eur Urol, 56, pp.81~88 (2009)
- del Popolo G, "Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients : a literature overview", Spinal Cord, 50, pp.8~13 (2012)
- Schurch B, "Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study", J Urol, 174, pp.196~200 (2005)
- Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
- Herschorn S, "Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial", J Urol, 185, pp.2229~2235 (2011)
- Ginsberg D, "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity", J Urol, 187, pp.2131~2139 (2012)
- Sussman D, "Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity", Neurourol Urodyn, 32, pp.242~249 (2013)
- Zhou X, "Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity : a systematic review and meta-analysis", Chin Med J(Engl), 128, pp.963~968 (2015)
- Zhang R, "OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences : a systematic review", Int Braz J Urol, 41, pp.207~219 (2015)
- Apostolidis A, "An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity", World J Urol, 31, pp.1469~1474 (2013)
- Ehren I, "Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study", Scand J Urol Nephrol, 41, pp.335~340 (2007)
- DerSimonian R, "Meta-analysis in clinical trials", Control Clin Trials, 7, pp.177~188 (1986)
- Foley SJ, "Vesico-ureteric reflux in adult patients with spinal injury", Br J Urol, 79, pp.888~891 (1997)
- Wefer B, "Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A(BO TOX)therapy in Germany", World J Urol, 28, pp.385~390 (2010)
- Khan S, "Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis", J Urol, 185, pp.1344~1349 (2011)
- Schurch B, "Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results", J Urol, 164(3 Pt 1), pp.692~697 (2000)
- Chancellor MB, "OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity", Neurology, 81, pp.841~848 (2013)
- Giannantoni A, "New therapeutic options for refractory neurogenic detrusor overactivity", Minerva Urol Nefrol, 56, pp.79~87 (2004)
- Reitz A, "European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity", Eur Urol, 45, pp.510~515 (2004)
- Abdel-Meguid TA., "Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial", J Urol, 184, pp.2423~2428 (2010)
- Nathan Hoag, "Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy", International Neurourology Journal, 20(1), pp.81~85 (2016), 대한배뇨장애요실금학회
- regardless of concomitant anticholinergic use or neurologic etiology, "Adv Ther", 2013, 819~833
- Dolly O., "Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins", Headache, 43(Suppl 1), pp.S16~S24 (2003)
- Ikeda Y, "Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder", Eur Urol, 62, pp.1157~1164 (2012)
- Apostolidis A, "Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity", Eur Urol, 49, pp.644~650 (2006)
- Finney SM, "Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome:motor or sensory actions?", BJU Int, 98, pp.503~507 (2006)
- De Laet K, "Adverse events after botulinum A toxin injection for neurogenic voiding disorders", Spinal Cord, 43, pp.397~399 (2005)
- Sauerwein D, "Urinary tract infection in patients with neurogenic bladder dysfunction", Int J Antimicrob Agents, 19, pp.592~597 (2002)
- Manack A, "Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database", Neurourol Urodyn, 30, pp.395~401 (2011)
- Kessler TM, "Clean intermittent self-catheterization after botulinum neurotoxin type A injections : short-term effect on quality of life", Obstet Gynecol, 113, pp.1046~1051 (2009)